Core Insights - Bolt Biotherapeutics is hosting a KOL conference call and webcast on May 12, 2025, featuring Dr. Ecaterina Dumbrava discussing the Phase 1 clinical study results of BDC-3042 [1][2] - The management team will also provide updates on BDC-4182 clinical development and first quarter 2025 financial results, followed by a live Q&A session [2] Company Overview - Bolt Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer treatment [4] - The company's pipeline includes BDC-3042, a first-in-class agonist antibody targeting dectin-2, and BDC-4182, a next-generation Immune-Stimulating Antibody Conjugate (ISAC) targeting claudin 18.2 [4] - BDC-3042 is currently in a Phase 1 dose escalation trial involving patients with seven different solid tumor types, while BDC-4182 is expected to initiate clinical trials in Q2 2025 [4]
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates